---
search:
  boost: .9
---

# Respiratory Agents - Antihistamines-Second Generation

[Criteria Document](https://mygainwell-my.sharepoint.com/:w:/g/personal/kaelyn_dobbins_gainwelltechnologies_com/EVnVqurlOaZGmAo8LlMrtNwBqQxtqnyfDEfpq-9eg16Ftg?e=RxgPwW){:target="_blank" rel="noopener}

|||
| ---------- | ---------------------------- |
| Criteria 1 | NP agents                    |
| Criteria 2 | Cetirizine Chewable (NP, AR) |

# Non-Preferred Products

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Respiratory Agents: Antihistamines – Second Generation</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Non-Preferred Products</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td> GCNSeqNo</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code(s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>CLARINEX-D</td>
<td>060403</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>DESLORATADINE</td>
<td>047763</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>DESLORATADINE</td>
<td>052159</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>DESLORATADINE</td>
<td>059683</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>FEXOFENADINE</td>
<td>031689</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>FEXOFENADINE</td>
<td>033716</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>FEXOFENADINE</td>
<td>061995</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>LEVOCETIRIZINE</td>
<td>048920</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>LEVOCETIRIZINE</td>
<td>062168</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number</strong></th>
<th><strong>Question ID</strong></th>
<th><strong>Default Next Question ID</strong></th>
<th><strong>Question Type</strong></th>
<th><strong>Question Text</strong></th>
<th><strong>Choice Text</strong></th>
<th><strong>Next Question ID</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1</td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request </td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3 </td>
<td>1000</td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">30 days</span> with at least <span class="underline">two different preferred</span> drugs? </p>
<p>The preferred alternatives may include the following: Cetirizine products, Loratadine products.</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Approve x 365 days)</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Approve x 365 days)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td><p>Y    </p>
<p> </p></td>
<td>END (Approve x 365 days)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>9</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 Days

|||
| ------------------ | --------- |
| **Last Approved ** | 5/16/2023 |
| **Other**          |           |

## Cetirizine Chewable

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Respiratory Agents: Antihistamines – Second Generation</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Cetirizine Chewable</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td> GCNSeqNo</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code(s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>CETIRIZINE CHEWABLE</td>
<td>053980</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>CETIRIZINE CHEWABLE</td>
<td>053981</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number</strong></th>
<th><strong>Question ID</strong></th>
<th><strong>Default Next Question ID</strong></th>
<th><strong>Question Type</strong></th>
<th><strong>Question Text</strong></th>
<th><strong>Choice Text</strong></th>
<th><strong>Next Question ID</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1</td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request </td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3 </td>
<td>1000</td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">30 days</span> with at least <span class="underline">two different preferred</span> drugs? </p>
<p>The preferred alternatives may include the following: Cetirizine products, Loratadine products.</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1004</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1004</td>
<td></td>
<td>Select</td>
<td>Is the patient 6 years of age and older?</td>
<td>Y</td>
<td>1005</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1005</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Is the patient unable to swallow a tablet and/or capsule formulation?</p>
<p>If yes, please submit documentation.</p></td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>9</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td><p>Y    </p>
<p> </p></td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>10</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>11</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 Days

|||
| ------------------ | --------- |
| **Last Approved ** | 5/16/2023 |
| **Other**          |           |
